Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial

James, Nicholas D, Prof ; Sydes, Matthew R, MSc ; Clarke, Noel W, Prof ; Mason, Malcolm D, Prof ; Dearnaley, David P, Prof ; Spears, Melissa R, MSc ; Ritchie, Alastair W S, MD ; Parker, Christopher C, MD ; Russell, J Martin, FRCR ; Attard, Gerhardt, MD PhD ; de Bono, Johann, Prof ; Cross, William, PhD ; Jones, Rob J, Prof ; Thalmann, George, Prof ; Amos, Claire, PhD ; Matheson, David, PhD ; Millman, Robin ; Alzouebi, Mymoona, FRCR ; Beesley, Sharon, FRCR ; Birtle, Alison J, MD ; Brock, Susannah, FRCR ; Cathomas, Richard, MD ; Chakraborti, Prabir, FRCR ; Chowdhury, Simon, MD ; Cook, Audrey, FRCR ; Elliott, Tony, PhD ; Gale, Joanna, DM ; Gibbs, Stephanie, FRCR ; Graham, John D, FRCP ; Hetherington, John, FRCS[Eng] ; Hughes, Robert, FRCR ; Laing, Robert, FRCR ; McKinna, Fiona, FRCR ; McLaren, Duncan B, FRCR, FRCP[Ed] ; O'Sullivan, Joe M, Prof ; Parikh, Omi, FRCR ; Peedell, Clive, FRCR ; Protheroe, Andrew, PhD ; Robinson, Angus J, FRCR ; Srihari, Narayanan, MD ; Srinivasan, Rajaguru, FRCR ; Staffurth, John, MD ; Sundar, Santhanam, FRCR ; Tolan, Shaun, MD ; Tsang, David, MCRP ; Wagstaff, John, Prof ; Parmar, Mahesh K B, Prof

The Lancet (British edition), 2016-03, Vol.387 (10024), p.1163-1177 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível